0
     

Report Added
Report already added
Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 2, 7, 1, 8, 3 and 2 respectively.

Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Nausea and Vomiting - Overview
Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
Acacia Pharma Ltd
AcuCort AB
Amzell BV
Aphios Corp
Arovella Therapeutics Ltd
Athenex Inc
Axim Biotechnologies Inc
Benuvia Therapeutics Inc
Bionorica SE
Camurus AB
Daewoong Pharmaceutical Co Ltd
Ethicann Pharmaceuticals Inc
Helsinn Group
Hoverink Biotechnologies Inc
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
LipoSeuticals Inc
LP Pharmaceutical (Xiamen) Co Ltd
Luxena Pharmaceuticals Inc
MannKind Corp
Senzer Ltd
Shackelford Pharma Inc
Skye Bioscience Inc
SoluBest Ltd
Starton Therapeutics Inc
Yichang Humanwell Pharmaceutical Co Ltd
Chemotherapy Induced Nausea and Vomiting - Drug Profiles
(fosnetupitant chloride hydrochloride + palonosetron hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(netupitant + palonosetron hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AMZ-004 - Drug Profile
Product Description
Mechanism Of Action
APD-403 - Drug Profile
Product Description
Mechanism Of Action
History of Events
aprepitant - Drug Profile
Product Description
Mechanism Of Action
aprepitant - Drug Profile
Product Description
Mechanism Of Action
aprepitant - Drug Profile
Product Description
Mechanism Of Action
dexamethasone - Drug Profile
Product Description
Mechanism Of Action
History of Events
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
dronabinol - Drug Profile
Product Description
Mechanism Of Action
dronabinol - Drug Profile
Product Description
Mechanism Of Action
dronabinol - Drug Profile
Product Description
Mechanism Of Action
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosnetupitant chloride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
frovatriptan dimeglumine - Drug Profile
Product Description
Mechanism Of Action
granisetron - Drug Profile
Product Description
Mechanism Of Action
History of Events
granisetron - Drug Profile
Product Description
Mechanism Of Action
History of Events
HR-20013 - Drug Profile
Product Description
Mechanism Of Action
LPI-1504 - Drug Profile
Product Description
Mechanism Of Action
LPI-1505 - Drug Profile
Product Description
Mechanism Of Action
NB-1222 - Drug Profile
Product Description
Mechanism Of Action
History of Events
olanzapine - Drug Profile
Product Description
Mechanism Of Action
History of Events
ondansetron - Drug Profile
Product Description
Mechanism Of Action
History of Events
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
palonosetron - Drug Profile
Product Description
Mechanism Of Action
palonosetron hydrochloride LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPID-301 - Drug Profile
Product Description
Mechanism Of Action
Zindol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Chemotherapy Induced Nausea and Vomiting - Dormant Projects
Chemotherapy Induced Nausea and Vomiting - Discontinued Products
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
Featured News & Press Releases
Mar 01, 2022: AcuCort is exempted from the application fee by the U.S. Food and Drug Administration
Feb 22, 2022: AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT
Feb 17, 2022: AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT
Dec 02, 2021: Helsinn announces European Commission approval of the liquid formulation of AKYNZEO (fosnetupitant/palonosetron)
Nov 30, 2021: ESMO: Fosnetupitant is valuable in the prophylaxis of acute, delayed, and beyond delayed cinv
Oct 05, 2021: AcuCort’s drug ISICORT demonstrates a three-year shelf life
Oct 05, 2021: REDUVO- A major milestone for Tetra Bio-Pharma
Sep 03, 2021: AcuCort receives a second US patent protection for its drug ISICORT
Jun 16, 2021: Starton Therapeutics phase 2 TROPIC-I clinical study will be first to use total control primary endpoint in superiority study
Jun 02, 2021: Health Canada accepts new drug submission for REDUVO as a treatment for patients with chemotherapy-induced nausea and vomiting
May 05, 2021: DanCann Pharma have signed a definitive distribution agreement with Tetra Bio-Pharma for the exclusive distribution of Reduvo Adversa and Qixleef in Scandinavia and Germany
May 03, 2021: Tetra Bio-Pharma granted a drug establishment license to distribute REDUVO soft gel capsules in Canada
Apr 26, 2021: AcuCort progresses into a new phase and strengthens the commercialization team
Apr 14, 2021: Tetra Bio-Pharma provides update on its New Drug Submission application in Canada
Apr 13, 2021: Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by AcuCort AB, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Amzell BV, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Arovella Therapeutics Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Axim Biotechnologies Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Benuvia Therapeutics Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Bionorica SE, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Ethicann Pharmaceuticals Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Group, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Hoverink Biotechnologies Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by IntelGenx Corp, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by LipoSeuticals Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by LP Pharmaceutical (Xiamen) Co Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Luxena Pharmaceuticals Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Senzer Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Shackelford Pharma Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Skye Bioscience Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Starton Therapeutics Inc, 2022
Chemotherapy Induced Nausea and Vomiting - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, 2022
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, 2022 (Contd..1)
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, 2022 (Contd..2)
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, 2022

List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Consumables Market by Product (Dental Implants, Orthodontics, Periodontics, Endodontics, Bridges, Crowns, Dentures, Clear aligners, Disinfectants, Pastes, Cups, Brushes, Accessories), End user (Dental Clinics, Hospitals) - Global Forecast to 2027

Dental Consumables Market by Product (Dental Implants, Orthodontics, Periodontics, Endodontics, Bridges, Crowns, Dentures, Clear aligners, Disinfectants, Pastes, Cups, Brushes, Accessories), End user (Dental Clinics, Hospitals) - Global Forecast to 2027

2022 Vietnam Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline